We respectfully report that our manuscript “Proteolytically-cleaved fragments of cell surface proteins stimulate a cytotoxic immune response against tumor-activated endothelial cells in vitro” was published as a research article in “Journal of Cancer Science & Therapy”. 
          
          Immunization with tumor-derived endothelial cells is of great demand in antiangiogenic therapy of all solid tumors. However, current cell-based vaccines are crude product and there are questions regarding their overall safety. We report in paper a simple and straightforward approach for preparing of antiangiogenic cancer vaccines.  Through treatment of tumor-activated endothelial cell cultures with purified protease, it is possible to make preparations of cell-surface antigens that are free of intracellular content and contain two orders-of-magnitude less protein than the whole lysate of an equivalent number of endothelial cells. Despite this difference in total protein content, protease-generated preparations stimulate anti-cancer responses from immune cells better those stimulated with endothelial cells themselves! Any cell contaminates and undesired intracellular content (cell parasites, viruses, toxins, prions, house-keeping proteins, etc.) are easily removes from vaccine by proposed method. Thus, endothelial cell-based vaccines may be improved by replacing endothelial cells with their isolated cell-surface antigens. Vaccines prepared in this manner are potentially more qualified, purer, and safer.

We thank you for your interest to our work.

BioBohemia